Literature DB >> 16456813

Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism.

Ramy Ibrahim1, Helen Frederickson, Allyson Parr, Yvona Ward, Joel Moncur, Samir N Khleif.   

Abstract

BACKGROUND: To date, several mechanisms have been described by which malignant cells escape from the immune system. One of these is through the expression of FasL. The authors hypothesized that the Fas/FasL interaction enables cervical carcinoma cells to induce apoptosis of the cells of the immune system and thereby escape from them.
METHODS: The authors tested the expression of FASL on the surface of cervical carcinoma tissues. Next, they stained the same cervical tissues with anti-human leukocyte common antigen and TUNEL to identify apoptotic cells. An in vitro functional assay was then done to test if the FASL expressed on the surface of cervical carcinoma cell lines was or was not responsible for inducing apoptosis in T-cells. Finally, they compared the expression of FASL on normal and dysplastic cervical tissues.
RESULTS: Ninety-four percent of the cervical carcinoma tissues the authors tested expressed FasL and the majority of the apoptotic cells in the specimens were leukocytes with very few tumor cells. In the in vitro functional assay, only the Fasl expressing cell line and not the Fasl negative cell line was able to induce apoptosis of the Fas-expressing Jurkat cells. On examining the normal cervical tissues, the authors found that the expression of Fasl was confined to the basal cell layer with loss of expression observed in the suprabasal layers, which made it an immune privileged site. Conversely, there was persistent expression of FasL in the dysplastic layers in cervical dysplasia and squamous cell carcinoma specimens.
CONCLUSIONS: The findings of the current study support the authors' hypothesis that persistent expression of FasL plays a role in the ability of cervical carcinoma cells to escape from the immune system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16456813     DOI: 10.1002/cncr.21697

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.

Authors:  Sateesh Reddy Nallapalle; Sarika Daripally; V T S Vidudala Prasad
Journal:  Tumour Biol       Date:  2014-12-04

2.  Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand.

Authors:  Eirini Taliouri; Thomas Vrekoussis; Aikaterini Vergetaki; Theodore Agorastos; Antonis Makrigiannakis
Journal:  Tumour Biol       Date:  2012-10-18

3.  Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population.

Authors:  M Erdogan; M Karadeniz; A Berdeli; S Tamsel; Y Ertan; H Uluer; C Yilmaz; M Tuzun; T Kabalak; A G Ozgen
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

4.  Expression of HLA-I, CD8, and CD4 and Their Clinical Significance in Cervical Cancer.

Authors:  Jiang Tao Fan; Yan Liao; Xiao Hui Si; Xiao Li Geng; Wei Wei; Qing Li Xie
Journal:  World J Oncol       Date:  2011-02-26

Review 5.  The immunoregulatory mechanisms of carcinoma for its survival and development.

Authors:  Caigan Du; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-01-21

6.  Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy.

Authors:  Luya Cai; Xuedan Du; Cheng Zhang; Shanshan Yu; Lixiao Liu; Jinduo Zhao; Ye Zhao; Chunhong Zhang; Jinting Wu; Bin Wang; Yingyu Chen; Xiaoping Su; Xiaojian Yan; Wenfeng Li
Journal:  Cancer Immunol Immunother       Date:  2021-11-03       Impact factor: 6.630

7.  Tim-3 expression in cervical cancer promotes tumor metastasis.

Authors:  Yang Cao; Xiaoxi Zhou; Xiaoyuan Huang; Qinlu Li; Lili Gao; Lijun Jiang; Mei Huang; Jianfeng Zhou
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.